MWNA
KNSA icon

Marshall Wace North America’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Marshall Wace North America’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,521
Closed -$651K – 1561
2018
Q3 		$651K Sell
25,521
-20,608
-45% -$401K ﹤0.01% 672
2018
Q2 		$800K Buy
+46,129
New +$835K ﹤0.01% 992

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Marshall Wace North America's KNSA Position: Q4 2018 in Review

Marshall Wace North America sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2018, closing a stake of 25,521 shares — an estimated $651K sold.

Marshall Wace North America first reported a position in KNSA in Q2 2018 and held it in 2 quarters. The position peaked at $800K in Q2 2018. 52 funds tracked by Wall St. Rank hold KNSA as of Q4 2018.

  • Marshall Wace North America reported no remaining Kiniksa Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 25,521 Kiniksa Pharmaceuticals shares in Q4 2018, an estimated $651K.
  • Marshall Wace North America first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Marshall Wace North America's Kiniksa Pharmaceuticals position peaked at $800K in Q2 2018.
  • 52 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.